AstraZeneca & Aptamer partner to bolster targeted siRNA therapies

Pharma giant AstraZeneca and UK biotech Aptamer Group are hoping to bolster the efficacy of small interfacing RNA (siRNA) therapies, using Aptamer’s Optimer delivery system.

The companies did not disclose the financials behind the collaboration but following the 3 July announcement, Aptamer’s shares were up by 18% to $0.95 (£0.74).